Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies

(2015) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD)

(2015) Brian G. Feagan et al.   GASTROENTEROLOGY

Su2079 Certolizumab Pegol Plasma Concentration and Clinical Remission in Crohn's Disease

(2015) William J. Sandborn et al.   GASTROENTEROLOGY

Sa2031 Accelerated Clearance of Serum Infliximab During Induction Therapy for Acute Ulcerative Colitis is Associated With Treatment Failure.

(2015) David Kevans et al.   GASTROENTEROLOGY

1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Tu1135 Serum Adalimumab and Immunogenicity in IBD Patients After 80mg Biweekly Maintenance Therapy

(2015) Ofer Ben-Bassat et al.   GASTROENTEROLOGY

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

(2013) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Mechanism of allopurinol induced TPMT inhibition

(2013) P.A. Blaker et al.   BIOCHEMICAL PHARMACOLOGY

Pharmacokinetics and Safety of Golimumab in Healthy Chinese Subjects Following a Single Subcutaneous Administration in a Randomized Phase I Trial

(2013) Yanli Zhuang et al.   CLINICAL DRUG INVESTIGATION

Sustained Clinical Benefit and Tolerability of Methotrexate Monotherapy After Thiopurine Therapy in Patients With Crohn's Disease

(2013) Margien L. Seinen et al.   Clinical Gastroenterology and Hepatology

Strategic Use of Immunosuppressants and Anti-TNF in Inflammatory Bowel Disease

(2013) Edouard Louis   DIGESTIVE DISEASES

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

(2013) Bella Ungar et al.   GUT

Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials

(2013) William J. Sandborn et al.   Journal of Crohns & Colitis

The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: Results from a prospective pharmacological study

(2013) M.L. Seinen et al.   Journal of Crohns & Colitis

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

(2013) Kang-Moon Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study

(2012) F. Zorzi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease

(2012) Ingrid Ordás et al.   Clinical Gastroenterology and Hepatology

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

(2012) Lior Katz et al.   INFLAMMATORY BOWEL DISEASES

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

(2012) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol

(2012) Melissa A. Smith et al.   Journal of Crohns & Colitis

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients

(2011) Y. González-Lama et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Thiopurine metabolite measurement - not for everyone

(2011) D. P. van Asseldonk et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

(2011) T. Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Meta-analysis

(2011) Ziwei Lin et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease

(2011) Laurent Peyrin-Biroulet et al.   GUT

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

(2011) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

(2011) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience

(2011) Michael B. Sprakes et al.   Journal of Crohns & Colitis

The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

(2010) U. Kopylov et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

(2010) A. Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

Predictive value of epithelial gene expression profiles for response to infliximab in Crohnʼs disease‡

(2010) Ingrid Arijs et al.   INFLAMMATORY BOWEL DISEASES

Lack of Racial Differences in the Pharmacokinetics of Subcutaneous Golimumab in Healthy Japanese and Caucasian Male Subjects

(2010) Jie Ling et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenetics of Immunosuppressant Polymorphism of CYP3A5 in Renal Transplant Recipients

(2010) J. Larriba et al.   TRANSPLANTATION PROCEEDINGS

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

(2009) Mohammad Tabrizi et al.   AAPS Journal

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab

(2009) C. MA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease

(2009) M. A. SMITH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

(2009) G. M. Bartelds et al.   ANNALS OF THE RHEUMATIC DISEASES

Advances in individual prediction of methotrexate toxicity: a review

(2009) Kjeld Schmiegelow   BRITISH JOURNAL OF HAEMATOLOGY

Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients

(2009) W Zhao et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics of Thiopurines in Inflammatory Bowel Disease

(2009) L. Derijks et al.   CURRENT PHARMACEUTICAL DESIGN

TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis

(2009) Trine Olsen et al.   CYTOKINE

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Budesonide for Crohn's disease

(2009) Cynthia H Seow et al.   Expert Opinion on Drug Metabolism & Toxicology

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

(2009) I. Arijs et al.   GUT

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease

(2008) A. ANSARI et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

(2008) R. L. WEST et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A 6-Thioguanine Nucleotide Threshold Level of 400 pmol/8 × 108Erythrocytes Predicts Azathioprine Refractoriness in Patients With Inflammatory Bowel Disease and Normal TPMT Activity

(2008) Xavier Roblin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Meta-Analysis of the Effect of MDR1 C3435T Polymorphism on Cyclosporine Pharmacokinetics

(2008) Zhi-Ping Jiang et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Inflammation and Altered Drug Clearance in Cancer: Transcriptional Repression of a Human CYP3A4 Transgene in Tumor-bearing Mice

(2008) GR Robertson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport

(2008) TD Nolin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Infliximab and methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of dosage regimens

(2008) Elias Zintzaras et al.   CLINICAL THERAPEUTICS

Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides

(2008) Sharon J. Gardiner et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity

(2008) Rebecca L. Roberts et al.   Pharmacogenetics and Genomics

An update on methotrexate pharmacogenetics in rheumatoid arthritis

(2008) Prabha Ranganathan   PHARMACOGENOMICS